Prime Medicine Reports First-in-Human Prime Editing Success for Chronic Granulomatous Disease in NEJM
核心洞察
Prime Medicine published Phase 1/2 clinical data for PM359 in the New England Journal of Medicine, marking the first-in-human demonstration of Prime Editing safety and efficacy for chronic granulomatous disease (搜索) treatment.
Two patients achieved rapid neutrophil engraftment with 69% and 83% dihydrorhodamine-positive neutrophils by Day 30, far exceeding the 20% minimum threshold for clinical benefit.
Both patients experienced durable restoration of NADPH oxidase (搜索) activity and early clinical benefits, including resolution of CGD-associated colitis (搜索) symptoms, without any safety concerns attributable to PM359.
Prime Medicine announced the publication of groundbreaking Phase 1/2 clinical data for PM359, its investigational autologous hematopoietic stem cell product for p47phox (搜索) chronic granulomatous disease (搜索) (CGD), in the New England Journal of Medicine. The study represents the first-in-human demonstration of Prime Editing's safety and efficacy, marking a significant milestone for the next-generation gene editing platform.
Clinical Trial Results Demonstrate Rapid Engraftment and Functional Recovery
The Phase 1/2 trial, designed to assess safety, biological activity and preliminary efficacy in adult and pediatric participants, enrolled two patients with histories of CGD-defining complications, including CGD-associated colitis (搜索) (CAC) and skin and soft tissue infections. Both patients were maintained on long-term prophylactic therapy prior to treatment.
Both patients experienced rapid neutrophil and platelet engraftment following PM359 infusion. By Day 30, the patients achieved 69% and 83% dihydrorhodamine-positive (DHR+) neutrophils, respectively, substantially exceeding the 20% projected minimum threshold for clinical benefit. The DHR activity remained stable over time in both patients, suggesting successful gene correction in the long-term repopulating hematopoietic stem cells of the bone marrow.
Sustained Clinical Benefits Without Safety Concerns
The treatment demonstrated durable restoration of NADPH oxidase (搜索) activity and early clinical benefits in both patients. Patient 1 discontinued mesalamine treatment and has not experienced a flare of CGD-associated colitis (搜索). Patient 2 showed substantial decreases in fecal calprotectin levels and resolution of chronic CAC symptoms. Both patients remain free of new CGD-related complications or significant intercurrent illnesses post-infusion.
Importantly, no clinically significant adverse events attributable to PM359 occurred in either patient. All observed toxicities were consistent with busulfan-based conditioning, indicating that the gene editing therapy itself was well-tolerated.
Prime Editing Platform Advantages
"Publication of these first-in-human data highlights Prime Editing's promise as a next-generation therapeutic platform, which is capable of delivering meaningful benefits to patients and which can be manufactured and delivered at clinical scale," said Mohammed Asmal, M.D., Ph.D., Chief Medical Officer of Prime Medicine.
The results offer insights into Prime Editing's potential advantages over other gene editing technologies. The study observed high recovery rates of viable corrected cells after a single mobilization cycle and rapid reconstitution of the hematopoietic system after infusion. These findings support the company's belief that Prime Editing's mechanism, which does not induce double-strand breaks, may be better tolerated by hematopoietic stem cells and other cell types compared to alternative approaches.
Broader Therapeutic Implications
Prime Medicine's proprietary Prime Editing platform is designed to make precise edits at specific positions within genes while minimizing unwanted DNA modifications. The technology has the potential to repair almost all types of genetic mutations and work across many different tissues, organs and cell types, potentially unlocking opportunities across thousands of indications.
The company is currently advancing a diversified portfolio of investigational therapeutic programs across liver, lung, immunology and oncology applications. The successful demonstration of Prime Editing in CGD provides validation for the platform's broader therapeutic potential in genetic diseases, immunological diseases, cancers, and infectious diseases.